[177Lu]Lu-AMTG首次人体血清稳定性研究:迈向改进的GRPR靶向放射性药物治疗的一步
本研究在转移性去势抵抗性前列腺癌患者静脉注射7.6 ± 0.1 GBq [177Lu]Lu-AMTG后采集血样,用反相高效液相色谱分析血清稳定性。注射后1小时,[177Lu]Lu-AMTG的体内血清稳定性为62% ± 6%,明显高于[68Ga]Ga-RM2的19% ± 2%。作者认为基于其高体内血清稳定性和良好的生物分布,放射性标记AMTG衍生物有潜力改进GRPR表达恶性肿瘤的放射性药物治疗。
要点
- 注射后1小时[177Lu]Lu-AMTG体内血清稳定性为62% ± 6%,高于[68Ga]Ga-RM2的19% ± 2%。
- 本研究为首次人体血清稳定性分析,静脉注射活度为7.6 ± 0.1 GBq。
- 作者认为放射性标记AMTG衍生物有潜力改进GRPR表达恶性肿瘤的放射性药物治疗。
核心结论
- 基于[177Lu]Lu-AMTG在人体内的高血清稳定性和良好的生物分布,放射性标记AMTG衍生物有潜力改进GRPR表达恶性肿瘤的放射性药物治疗。
研究设计与样本
- 本研究为首次人体血清稳定性研究,受试者静脉注射7.6 ± 0.1 GBq [177Lu]Lu-AMTG后于不同时间点采集血样并离心,血清样本经反相高效液相色谱分析。
主要发现
- 注射后1小时,[177Lu]Lu-AMTG的体内血清稳定性(均值 ± 标准差)为62% ± 6%,[68Ga]Ga-RM2为19% ± 2%,前者明显高于后者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of PET/CT with gastrin-releasing peptide receptor (GRPR) ligand [68Ga]Ga-AMTG has recently been shown to diagnose metastatic disease not detected by 18F-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer. This study aimed to analyze the serum stability of [177Lu]Lu-AMTG in human subjects due to the compound's high stability observed preclinically and to elucidate its therapeutic potential. Methods: Blood samples were collected at various time points after intravenous injection of 7.6 ± 0.1 GBq of [177Lu]Lu-AMTG and centrifuged. Serum samples were analyzed via reversed-phase high-performance liquid chromatography. Results: At 1 h after injection, the mean ± SD in vivo serum stability of [177Lu]Lu-AMTG was distinctly higher (62% ± 6%) than that of [68Ga]Ga-RM2 (19% ± 2%). Conclusion: Based on the high in vivo serum stability of [177Lu]Lu-AMTG in humans and favorable biodistribution, radiolabeled AMTG derivatives have the potential to improve radiopharmaceutical therapy for GRPR-expressing malignancies.
引用
- Felber V, Holzleitner N, Joksch M, et al. First-in-Human Serum Stability Studies of [177Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2025. PMID: 40306971. doi:10.2967/jnumed.124.269132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。